The goal of cancer immunotherapy is to elicit a robust immune response to search, recognize, engage, and eradicate cancer cells. In a normal, healthy person our immune cells, in particular, T cells, play a vital role in recognizing tumors and removing them.
Despite the approval of immunotherapies such as Keytruda (anti-PD-1), Opdivo (anti-PD-1), Yervoy (anti-CTLA-4) and Tecentriq (anti-PD-L1), there are a number of factors that lead to therapy resistance in patients. However, thanks to breakthroughs in cancer research coupled with technological advancements, several factors have been identified that impede the ability of immune cells to effectively recognize and kill tumors. These factors include:
Evading recognition by T cells
Influencing T cell trafficking and infiltration
Affecting T cell metabolism
Dysregulation the function of T cells
Resisting killing by T cells
Inducing apoptosis of T cells
So where do we go from here?
Streamline the traditional services model
Be creative in how we offer our services
Cost-effective to cater to all our partner’s needs (from start-up to big pharma)